Evestia Clinical acquired Atlantic Research Group on July 31, 2025, expanding its presence in the United States and bolstering its capabilities in oncology and rare disease clinical research. Evestia, a European-based clinical research organization (CRO), was carved out from Bionical Emas by Kester Capital and its management team in December 2024. The acquisition of Atlantic Research Group, which specializes in the same therapeutic areas as well as neurology, enhances Evestia's service offerings and geographic footprint.

Deal structure and financing

Kartesia provided senior financing for the acquisition through a combination of its Senior Opportunities (KSO) Strategy and SMAs (Strategic Minority Acquisitions). The exact equity-debt split is not disclosed. Kartesia's financing enabled Evestia to acquire Atlantic Research Group without revealing specific financial details such as leverage metrics or lock-up terms. It is also unclear if the sellers retained any stake in the combined entity.

Strategic context

Evestia Clinical, established by Kester Capital and its management team from Bionical Emas in December 2024, sought to expand its operations into the United States through the acquisition of Atlantic Research Group. The strategic rationale for this move is evident: Evestia aims to solidify its position as a leading CRO with expertise in oncology and rare diseases by integrating ARG's capabilities and geographical reach. This expansion aligns with broader industry trends, where specialized CROs are consolidating their market positions through targeted acquisitions that enhance their service offerings and geographic distribution.

Regulatory path

The acquisition of Atlantic Research Group did not require any significant regulatory approvals or remedies, as the deal falls below threshold levels for mandatory filings under U.S. antitrust laws (HSR Act) and EU merger control regulations. However, Evestia may have voluntarily submitted notifications to relevant authorities in specific jurisdictions where ARG operates due to local market concentration concerns. The transaction's timeline indicates that it was structured and financed efficiently without major regulatory hurdles.

Kartesia’s support underscores the strategic importance of this acquisition for Evestia Clinical as it seeks to establish a robust global presence in specialized clinical research services.